Background: The aim of this study was to determine the maximum-tolerated dose (MTD), safety, pharmacokinetics, and pharmacodynamics of OPB-51602, an oral, direct signal transduction activator of transcription 3 (STAT3) inhibitor, in patients with refractory solid tumors.
Results: Fifty-one patients were studied at 2, 4, and 5 mg per day dosing. The MTD was 5 mg; first-cycle dose-limiting toxicities (DLTs) were grade 3 hyponatremia in one patient, and grade 3 dehydration in another. Intermittent dosing of both 2 and 4 mg doses were tolerable, and the recommended phase II dose was 4 mg. Cohort B investigated 4 mg intermittently, whereas cohort C investigated 4 mg continuously. Common toxicities included fatigue, nausea/vomiting, diarrhea, anorexia, and early-onset peripheral neuropathy. Drug-induced pneumonitis occurred in two patients in cohort C. Continuous dosing was associated with a higher incidence of peripheral neuropathy and a lower mean relative dose intensity, compared with intermittent dosing. Steady-state pharmacokinetics was characterized by high oral clearance, mean elimination half-life ranging from 44 to 61 h, and a large terminal-phase volume of distribution. An active metabolite, OPB-51822, accumulated to a greater extent than OPB-51602. Flow cytometry of peripheral blood mononuclear cells demonstrated pSTAT3 (Tyr 705 ) inhibition following exposure. Two patients achieved partial responses at 5 mg intermittently and 4 mg continuously; both had epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) with prior EGFR tyrosine kinase inhibitor exposure.
introduction
The signal transduction activator of transcription (STAT) proteins are a family of cytoplasmic transcription factors. STAT3 is constitutively activated in human malignancies within both tumor and immune cells in the microenvironment, promoting cell proliferation, survival, angiogenesis, and tumor-mediated immune suppression. Activation of STAT3 can occur via Janus-activated kinases (JAK) recruited by ligand-bound cytokine receptors, or activated growth factor receptor (e.g. epidermal growth factor receptor, EGFR) and non-receptor (e.g. Src) tyrosine kinases. These trigger STAT3 tyrosine (Tyr) 705 phosphorylation, forming activated dimers that translocate to the nucleus to promote target gene transcription [1, 2] . Another C-terminus site, serine (Ser) 727 , is phosphorylated by mitogen-activated protein kinase signaling and enhances STAT3 transcription activity [3] . STAT3 is an attractive therapeutic target since it mediates multiple oncogenic signaling pathways and tumor-promoting inflammatory states. However, there have been significant challenges in developing STAT3 inhibitors. While multiple compounds targeting STAT3 pTyr-SH2 and DNA-binding domains, or upstream components of the STAT3 pathway, have been evaluated, few have reached clinical development due to unfavorable physiochemical properties, lack of specificity, or biologic activity [4] .
OPB-51602 (Otsuka Pharmaceutical, Japan) is an orally active low-molecular-weight inhibitor of STAT3 phosphorylation (Tyr 705 / Ser 727 ). Using computational docking, molecular dynamic simulation, and in vitro-binding assays, OPB-51602 has been found to bind with high affinity to a distinct pocket in the STAT3 SH2 domain and to interfere with STAT3 functions in both tumor cells and xenografts [5] . Furthermore, OPB-51602 strongly inhibits STAT3 phosphorylation without significant off-target effects on other tyrosine or serine/threonine kinases including EGFR, JAK1-3, and Src kinase (Otsuka IB). Potential off-target effects are being investigated preclinically.
On the basis of its favorable preclinical activity and tolerability, OPB-51602 was evaluated in this first-in-human phase I clinical trial, to determine its maximum-tolerated dose (MTD), pharmacokinetics (PK), pharmacodynamics, and antitumor effects in patients with refractory solid malignancies.
patients and methods

patient selection
Eligible patients were aged 21 years (the legal age of consent in Singapore) and above, with an Eastern Cooperative Oncology Group performance status of 0-1, and life expectancy exceeding 3 months. All had solid tumors refractory to standard treatment or for which no standard therapy existed. Patients were capable of swallowing tablets and fulfilled the following criteria: neutrophils ≥1500/µl, hemoglobin ≥9 g/dl, platelets ≥75 000/µl, serum creatinine <1.5× upper limit of normal (ULN), liver enzymes ≤2.5× ULN (or <5× ULN in the presence of liver metastases), and total bilirubin <2.5× ULN.
Exclusion criteria included uncontrolled central nervous system metastases, concurrent infection, second malignancy within 5 years, and significant cardiovascular disease. Patients with severe gastrointestinal disorders, existing interstitial pneumonitis, and those who were HIV seropositive, pregnant, or lactating were excluded. The study protocol was approved by institutional ethics and regulatory authorities; all participants provided written informed consent.
study design
This single-arm, open-label phase I trial was conducted in three cohorts: a sequential dose escalation in cohort A to establish the MTD of OPB-51602 administered on an intermittent schedule (days 1-14 every 21 days) based on preclinical pharmacokinetic studies, cohort B was an expansion cohort evaluating the tolerability of the dose lower than the MTD, and cohort C evaluated a continuous daily dosing (CDD) schedule in 28-day cycles. The aim of CDD was to induce sustained STAT3 suppression.
OPB-51602 was available as 2, 5, and 25 mg tablets. The starting dose was 2 mg (equivalent to 1/10 of rat no-observable-adverse-events-level dose in the more susceptible species). Dose escalations were planned at 5, 10, 20, 40, 60, 80, and 100 mg. Using a 3 + 3 dose escalation design, patients were enrolled in cohorts of three, with expansion to six patients if dose-limiting toxicities (DLTs) occurred in any of the patients in the first cycle. DLT was defined as follows: grade 3 or 4 neutropenia with fever; grade 4 neutropenia or grade 3 thrombocytopenia ≥7 days; grade 4 thrombocytopenia; and any treatment-related grade 3 or 4 adverse events (AEs) including nausea, vomiting, and/or diarrhea despite the optimal use of anti-emetic and anti-diarrheal drugs. All subjects who received at least one dose of OPB-51602 were evaluable for DLTs; any subject withdrawn before completion of cycle 1 for reasons other than DLT was deemed non-evaluable for response and replaced. Dose escalation continued until MTD was reached, defined as the lowest dose at which DLT was observed in two or more patients of a cohort in cycle 1. The recommended phase II dose was the next lower dose level. A maximum of two dose reductions was allowed and no intrapatient dose escalation was permitted. Administration of OPB-51602 continued until unacceptable toxicity, consent withdrawal, disease progression, or death.
study assessments
Safety evaluations occurred at baseline and weekly intervals for the duration of treatment, and within 15 days of last dosing. Evaluations included physical examination, electrocardiography, and laboratory studies (hematology, clinical chemistries, and urinalysis). The serial monitoring of serum lactate was introduced in cohort C, after preclinical data demonstrated lactate accumulation in OPB-51602-treated cells. AEs were graded according to the Common Terminology Criteria for Adverse Events (version 4.0).
Radiologic assessment was carried out during screening, after cycle 1 and every two cycles thereafter. Post-cycle 1 tumor assessments were carried out based on the findings of early tumor response with continuous dosing in animal xenograft models (data on file, Otsuka Pharmaceutical). In cohorts B and C, 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET)/ CT scan was used for baseline and post-cycle 1 assessment. FDG-PET/CT or routine CT imaging was permitted for subsequent assessments. Lesions were evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and EORTC PET response criteria [6] .
pharmacokinetic assessments
In cohorts A and B, plasma PK sampling for the concentrations of OPB-51602 and its known metabolites was carried out in cycle 1 on days 1 (single-dose PK) and 17 (multiple-dose PK; supplementary File S1, available at Annals of Oncology online).
pharmacodynamic and biomarker assessments
In cohorts B and C, the pharmacodynamic effect of OPB-51602 was evaluated in patients' peripheral blood mononuclear cells (PBMCs) by comparing the percentage of CD45-positive cells displaying pSTAT3 (Tyr
705
) at baseline and post-treatment. Available archival tissue was subjected to pSTAT3 (Tyr 705 ) immunohistochemistry, and non-small-cell lung cancer (NSCLC) specimens were evaluated for EGFR mutation and Echinoderm microtubuleassociated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) translocations (supplementary File S1, available at Annals of Oncology online).
statistical analysis
Comparisons between pharmacokinetic and pharmacodynamic parameters were carried out using Student's t-test, χ 2 testing, or equivalent non-parametric tests. Correlations were carried out with Pearson correlation. Relative dose intensity (RDI) was defined as the ratio of the actual mean dose delivered per week to the scheduled mean total weekly dose over the period of treatment expressed as a percentage. All P-values were two-sided and level of significance was P ≤ 0.05. Statistical analysis was carried out using SPSS v13.0 (SPSS, Inc., Chicago, IL, USA). Table 1 ). They were heavily pretreated, with the majority (75%) having received greater than or equal to three prior lines of systemic therapy. Twenty patients were treated in cohort A at 2, 4, and 5 mg dose levels; 12 patients were treated in cohort B at 4 mg on the same 2 week-on, 1 week-off schedule, and 19 patients were treated in cohort C at 4 mg CDD. Cohorts B and C were enriched for NSCLC patients.
dose escalation and MTD
In cohort A, 20 patients received at least one dose of OPB-51602; all were assessable for first-cycle toxicities, whereas two patients were assessable for toxicities but not for response as they discontinued study treatment due to non-drug-related pneumonia (2 mg) and consent withdrawal (5 mg). No DLTs were observed in the first cohort of three patients receiving 2 mg. MTD was reached at the next dose level of 5 mg as two of six assessable patients experienced first-cycle DLTs (grade 3 hyponatremia and grade 3 dehydration). The first was a patient with metastatic pancreatic cancer, who developed grade 1 treatment-related anorexia, nausea, vomiting, and diarrhea. She was admitted 2 weeks after initial dosing with grade 3 hyponatremia, where her serum sodium fell to 125 mmol/l from a baseline value of 136 mmol/l. She was treated with an intravenous saline infusion and recovered well. The second was a metastatic breast cancer patient who developed grade 1 vomiting and grade 2 diarrhea shortly after initial dosing. She was found to be significantly dehydrated on week 2, and required hospitalization for intravenous hydration. In both instances, dosing was interrupted temporarily and resumed at a lower dose of 2 mg following resolution of the serious AEs. After MTD was reached, a further three patients were treated at 2 mg without significant treatment-related toxicities, following which an intermediate dose of 4 mg was investigated. Six patients were treated at the 4-mg dose level for a median of three cycles (range: 1-6) without DLTs. This was therefore established as the recommended dose.
safety and tolerability Table 2 summarizes all treatment-related AEs observed. The most common AEs observed were nausea, vomiting, diarrhea, anorexia, peripheral neuropathy, and fatigue. Nausea and vomiting typically occurred 3-4 h following dosing. There were no treatment-related mortalities. Twelve patients were treated with 4 mg (days 1-14 every 21 days) in the expansion cohort B, all of whom were assessable for toxicity in cycle 1. This dose was found to be tolerable with only one patient with metastatic NPC experiencing significant grade 3 peripheral sensory and motor polyneuropathy during cycle 1.
Thereafter, 19 patients were enrolled into cohort C (4 mg CDD); of whom, 3 (16%) developed grade 3 or 4 AEs in the first cycle. The first was a metastatic gastrointestinal stromal tumor patient who developed grade 3 metabolic acidosis concomitantly with pneumonia, and the second was an NPC patient who experienced grade 3 peripheral neuropathy. Two NSCLC patients developed pneumonitis (grade 2 and 4), neither of whom had prior chest irradiation or recent EGFR tyrosine kinase inhibitor (TKI) use. Both were treated with intravenous steroids and recovered rapidly. Six patients from cohort C had serial serum lactate monitoring. Asymptomatic hyperlactemia occurred in two patients; in one instance, serum lactate levels rose to 7.1 mmol/l (day 21 and cycle 1) from a baseline of 1.7 mmol/l. Neither demonstrated apparent alternative clinical etiology, and rapid full reversal was observed in both upon OPB-51602 withdrawal.
Comparing the interrupted dosing and continuous dosing cohorts, there was significantly less nausea and vomiting in cohort C than other cohorts due to more optimal use of prophylactic anti-emetics, including 5-hydroxytryptamine (5-HT) 3 receptor antagonists and metoclopramide. However, the incidence of peripheral neuropathy was significantly higher in cohort C (63% versus 34%, P = 0.046; cohort C versus other cohorts). Although this manifested predominantly as sensory numbness, painful paresthesia and lower limb weakness occurred in four patients. The median time to onset of neuropathy was 17 days after the first dose and only 21% experienced symptom resolution within 30 days of OPB-51602 discontinuation. There was no correlation between the development of peripheral neuropathy and pre-existing diabetes mellitus or chemotherapyinduced peripheral neuropathy. Neuropathy led to treatment discontinuation in three patients, dose interruption in one, and dose reduction in another.
Notably, two patients in cohort A developed unusual infections, namely palmar herpes simplex and acute epididymoorchitis, while receiving OPB-51602 at 4 and 5 mg, respectively. No significant myelosuppression was observed apart from grade 1 thrombocytopenia in a patient treated at 4 mg, which was attributed either to OPB-51602 or the concomitant administration of pregabalin. One patient developed grade 3 neutropenia, but was subsequently diagnosed with myelodysplastic syndrome. Grade 2 QTc interval prolongation was observed at 4 mg, but there were no other significant cardiac events.
Six (32%) patients discontinued treatment in cycle 1 due to drug-related toxicities in cohort C, compared with 1 (8%) in cohort B. Overall, the mean RDI was 77.8 ± 24.7% and there was significantly lower tolerability (mean RDI: 68.4 ± 30.7% versus 85.1 ± 9.6%; P = 0.058) in cohort C compared with cohort B. 
pharmacokinetic evaluation
Single-and multiple-dose pharmacokinetic data were available for 50 and 31 patients, respectively (Table 3 and supplementary Figure S1 , available at Annals of Oncology online). Day 1 concentrations were too low to define the terminal elimination curve; at steady state, for the 4-mg dose, maximum plasma concentrations were between 3 and 4 h post-dosing, with a relatively long mean terminal elimination half-life of ∼60 h, oral clearance of 122.4 + 45.8 l/h (coefficient of variation of 37%), and large volume of distribution at terminal phase, suggesting extensive tissue binding. Doses of 4 mg or higher achieved maximal concentrations, albeit briefly, that were relevant for antitumor activity (≥2.54 ng/ml) based on H1299 NSCLC cell-line models (Otsuka IB). In addition, there was significant accumulation of drug concentrations with repeated dosing. OPB-51822, a demethylated active metabolite of OPB-51602, similarly showed long terminal half-life and accumulated to a greater extent (more than five-fold) than the parent drug at steady state, suggesting that it may significantly contribute to the pharmacodynamic effect of OPB-51602 treatment. There was no correlation between oral clearance and baseline clinical or laboratory values (data not shown).
tumor response
Thirty-seven patients were assessable for radiologic response after cycle 1 (supplementary Figure S2A , available at Annals of Oncology online). Their median duration on study treatment was 30 days (range: 9-213 days; supplementary Figure S2B , available at Annals of Oncology online). Two (5%) patients achieved confirmed partial response; both had EGFR mutationpositive NSCLC with prior documented progression on EGFR TKI treatment. The first patient was a 64-year-old female neversmoker with EGFR exon 19 deletion NSCLC who had received erlotinib for 18 months followed by two lines of chemotherapy. She received OPB-51602 at 5 mg and post-cycle 1 radiologic evaluation revealed complete resolution of the target lesion, a right lower lobe biopsy-proven pleural based metastasis, whereas non-target miliary lung lesions remained present. She received 10 cycles of treatment and remained progression-free for 6.9 months. Immunohistochemistry of her pretreatment pleural nodule biopsy showed high nuclear expression of pSTAT3 (Tyr   705 ). The second one was a 74-year-old male ex-smoker with EGFR exon 21 L858R mutant NSCLC. He had received gefitinib for 16 months followed by one line of chemotherapy. He received OPB-51602 at 4 mg CDD and achieved a 41% reduction in measurable tumor lesions at post-cycle 1 radiologic evaluation. He remained on study medication for five cycles, but required dose reduction for grade 3 peripheral neuropathy after three cycles. Progression-free intervals were 11, 4, and 5 months in three other patients with CRC (2 mg dose), endometrial cancer (4 mg dose), and NSCLC (4 mg CDD), respectively.
Nineteen patients treated at 4 mg were assessable for early metabolic response. The seven (37%) patients with metabolic responses included one NPC and six NSCLC patients; of whom, 50% were EGFR mutation-positive.
biomarker assessments Preclinical studies have provided compelling evidence for the critical role of STAT3 as a mediator of oncogenic signaling and tumor-induced immunosuppression, making it a highly attractive therapeutic target. We report on a first-in-man phase I study of OPB-51602, a novel direct and specific small-molecule STAT3 inhibitor without upstream kinase inhibitory activity, where preclinical studies supported an intermittent dosing schedule. The recommended phase II dose was 4 mg daily, on a 2-week-on, 1 week-off schedule. Nausea and vomiting coincided with maximum concentrations daily, and could be ameliorated with 5-HT3 serotonin receptor antagonists; however, the observed DLTs at 5 mg occurred despite optimal anti-emetics and antidiarrheal support, and are likely true DLTs. Furthermore, the significant incidence of study drug discontinuation due to intolerability as well as grade 3 peripheral neuropathy and hyperlactemia at the 4-mg dose level ( particularly in cohort C) supports our dose escalation decisions. The peripheral neuropathy was early in onset and did not appear cumulative, suggesting a different molecular mechanism compared with other forms of chemotherapy-induced neuropathy. Neurons are highly susceptible to oxidative stress, and pSTAT3 (Ser 727 ) has been shown to be crucial for neuronal survival through its effect on mitochondria function [7] . In vitro, nerve growth factor has been found to stimulate neurite outgrowth through the induction of pSTAT3 (Ser 727 ) in the mitochondria, but not in the nucleus [8] . This suggests that the observed neuropathy is an on-target effect. As neuropathy was more common and severe with continuous dosing, we postulate that less frequent dosing might mitigate this neurotoxicity. In addition, uncoupling of cellular metabolism through pSTAT3 (Ser 727 ) inhibition may have led to pyruvate and lactate accumulation, accounting for the hyperlactemia observed in several patients.
With the occurrence of epididymo-orchitis and palmar herpes simplex in our cohort, we postulate that OPB-51602 may result in increased opportunistic infections. JAK-STAT inhibitors, like tofacitinib, are associated with increased infections, whereas inactivating STAT3 mutations may result in staphylococcal infections and recurrent pneumonia, suggesting that patients on OPB-51602 should be monitored for opportunistic infections [9] .
Pharmacokinetics showed that maximum concentrations of OPB-51602 at steady state reached biologically relevant concentrations at 4 mg, albeit briefly. Long terminal t ½ of both OPB-51602 and its active metabolite indicates that less frequent dosing should be explored in future. As proof-of-inhibition of STAT3 phosphorylation, pSTAT3 (Tyr 705 ) fraction in PBMCs was reduced in a time-course manner with nadir between 4 and 8 h, corresponding to OPB-51602 t max . However, this inhibition was modest with this dosing regimen, with wide confidence intervals.
Encouraging antitumor activity was observed within this cohort of heavily pretreated patients, with 5% of the cohort obtaining objective responses, 11% remaining progression-free for >12 weeks, and tolerability of dosing for up to 10 cycles. The clinical activity observed in two NSCLC patients whose tumors contained activating EGFR mutations was intriguing, considering they had documented EGFR TKI resistance. STAT3 is a downstream component of the EGFR signal transduction pathway and indeed, STAT3 (Tyr 705 ) was activated in the NSCLC patient who achieved the best objective response. Concordantly, existing in vitro data have demonstrated the importance of pSTAT3 in mediating oncogenesis in EGFR mutation-positive NSCLC [3] . Emerging data suggest that STAT3 mediates treatment resistance to primary kinase inhibition in oncogene-addicted cancer models (e.g. EGFR, Human epidermal growth factor receptor 2, and ALK), where mitogen-activated extracellular signal-regulated kinase inhibition triggers the autocrine activation of STAT3 via fibroblast growth factor receptor and JAK [10] . The efficacy of OPB-51602 observed in EGFR TKI-resistant NSCLC patients lends support to these data, and emphasizes the potential role for STAT3 as a co-target in combating resistance to primary kinase inhibition. However, both responding patients were dosed at levels that are not being pursued further and tumor samples after progression with EGFR TKIs were unavailable for mutational analysis. It would also be pertinent to study the efficacy of OPB-51602 in conditions with activating STAT3 SH2 domain somatic mutations, e.g. the rare granular large cell lymphocytic leukemia [11] .
Compared with another STAT3 inhibitor, OPB-31121, OPB-51602 demonstrated superior oral bioavailability, and AEs in common included dose-limiting diarrhea, vomiting, and lactic acidosis [12] .
conclusions
In conclusion, this initial clinical experience with OPB-51602 demonstrates promising antitumor activity, particularly in NSCLC. Continuous dosing poses tolerability issues, and given its long half-life, less frequent dosing should be explored. Future direction for this compound includes the investigation of weekly dosing in oncogene-addicted cancers, with improved monitoring of peripheral neuropathy and hyperlactemia, as well as collection of prospective tissue biomarker.
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